Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Samples from patients that prove negative for DeltaF508 will be automatically routed to the Ambry Test: CF AMPLIFIED® for the most comprehensive analysis available. With a detection rate of approximately 99%, no other test can identify more mutations than the Ambry Test: CF AMPLIFIED.
Ambry Genetics President & CEO, Charles L. M. Dunlop, explains: "508 FIRST is the optimum start point for complete gene analysis of any Cystic Fibrosis patient. 508 FIRST provides a quick and affordable screen for the most likely positive result, with the security and confidence of full gene analysis in a single test."
"The certainty that comes with precise genetic results can reduce the cost of further tests, and help doctors provide the most effective care," Mr. Dunlop said. Because Ambry Genetics treats both phases of 508 FIRST as a single test, the process of arriving at definitive diagnosis of CF is covered more easily by insurance.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com